- Nov 13, 2018Phase 2 Data for Galmed Pharmaceutical's Aramchol™ in Non-Alcoholic Steatohepatitis (NASH) Presented During Late-Breaking Abstract Oral Session of The Liver Meeting® 2018The Phase 2b data has identified Aramchol 600mg as potentially effective to resolve NASH and improve fibrosis
Nov 5, 2018- Conference Call and Webcast Today at 8:30 a.m. EST / 5:30 a.m. PST -
- Oct 29, 2018Galmed Pharmaceuticals to Report Third Quarter 2018 Financial Results and Provide Business Update on Monday, November 5
- Oct 2, 2018Galmed Pharmaceuticals Announces a Late-Breaking Abstract on Aramchol™ to be Presented at the American Association for the Study of Liver Diseases (AASLD) - The Liver Meeting®
- Sep 27, 2018Galmed Pharmaceuticals to Present at the Cantor Global Healthcare Conference, ROTH Battle of the NASH Thrones Investor Conference and Stifel Healthcare Conference
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol™, a once-daily, oral therapy for...